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Abstract
The ETV6 gene encodes an ETS family transcription factor that is involved in a myriad of chromosomal
rearrangements found in hematological malignancies and other neoplasms. A recurrent ETV6 translocation,
previously described in patients with acute myeloid leukemia (AML) (Genes Chromosomes Cancer 51:328–337,2012,
Leuk Res 35:e212-214, 2011), whose partner has not been identified is t(7;12)(p15;p13). We herein report that the
t(7;12)(p15;p13) fuses ETV6 to ANLN, a gene not previously implicated in the pathogenesis of hematological
malignancies, and we demonstrate that this translocation leads to high expression of the fusion transcript in the
myeloid and lymphoid lineages.
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Background
Balanced translocations leading to chimeric fusion genes
play a major role in the pathogenesis of cancer. ETV6 is a
frequently rearranged gene involved in least 30 fusion genes
in myeloid and lymphoid neoplasms [1]. A recurrent ETV6
translocation, previously described in patients with acute
myeloid leukemia (AML), whose partner has not been
identified is t(7;12)(p15;p13) [2, 3]. In the present work we
describe the identification of ANLN as a novel ETV6 fusion
partner as a result of the t(7;12)(p15;p13).
Results
After Institutional Review Board approval (IRB-
25000.179520/2011-36) and signing of consent form, we
studied a 40 year-old female patient (P005) with diagnosis
of JAK2 V671F-positive primary myelofibrosis (PMF) and
karyotype compatible with 46,XX,del(5)(q12q33) since
2010. She had been treated with supportive care and
ruxolitinib. In 2013, the patient presented worsening of
blood counts and increase in spleen size, suggesting
disease progression. A bone marrow (BM) biopsy showed
an increase in BM fibrosis (grade 3 out of 3) and 9 %
blasts in the BM aspirate. Chromosomal analysis of BM
cells showed 46,XX,del(5)(q12q33),t(7;12)(p15;p13) [20]
(Fig. 1a). The patient was treated with an allogeneic BM
transplantation from her HLA-haploidentical sister. Seven
months after transplantation, she progressed to refractory
acute megakaryoblastic leukemia that presented with two
BM blast populations, a CD34-positive (4.9 %) and a
CD34-negative (49.6 %).
At the time of disease progression before transplant-
ation, a sample of her BM aspirate was analyzed by a
hybrid-capture-based comprehensive genomic profiling
assay (FoundationOne Heme), employing both DNAseq
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and RNAseq in a CLIA certified laboratory (Foundation
Medicine, Cambridge, MA, USA). This method evaluates
the entire coding sequence of 405 cancer-related genes, 31
selected introns frequently involved in rearrangements
and RNA sequencing of 265 genes commonly fused in
cancer. The result revealed three genomic alterations:
JAK2 V617F, NRAS G13D and an ETV6-ANLN fusion.
The fusion breakpoints occurred in intron 1 of both
genes, leading to a putative transcript carrying ETV6 first
exon fused to ANLN exons 2 to 25. We confirmed the ex-
pression of the fused gene by means of cDNA polymerase
chain reaction (PCR) and Sanger sequencing (Fig. 1b).
ANLN encodes an actin-bindig protein essential to
cytokinesis that is expressed at low levels in most nor-
mal tissues [4]. The protein encoded by ANLN consists
of one,125 amino acids and contains an actin-binding re-
gion (amino acids 231 to 676), an Anilin domain (amino
acids 799–953), a C-terminal pleckstrin homology do-
main (amino acids 983–1107) and a nuclear localization
region (amino acids 1–230) [4, 5]. The putative protein
encoded by the ETV6-ANLN fusion described here sub-
stitutes the first 6 ANLN amino acids (MDPFTE) by the
first 11 ETV6 amino acids (MSETPAQSSIK), resulting in
a protein almost identical to ANLN, without disrupting
its main functional domains. It is unknown at this
time if this change disrupts ANLN function. On the
other hand, this protein lacks all ETV6 functional
domains. We therefore hypothesized that the leukemogenic
mechanism operating in this case could be related to the
overexpression of the fusion protein, which can have very
similar functional characteristics to wild type ANLN.
We thus designed two Taqman qPCR assays (Life
Technologies) to study the expression level of the fusion
gene and also the expression of wild type ANLN in healthy
volunteer donors and patients with myeloid malignancies.
In order to evaluate only the expression of wild type
ANLN, we designed primers complementary to ANLN
exon 1 and exon 2. Since the fusion gene lacks ANLN
exon 1, only wild type ANLN was amplified. For the fusion
assay, primers were complementary to ETV6 exon 1 and
ANLN exon 2. We evaluated the expression of both tran-
scripts in the following magnetic bead selected cell popu-
lations: granulocytes (CD66b+) from 20 patients with
PMF and 8 healthy volunteers, in CD34+ cells from 10
AML patients and on myeloblasts (CD34+), bone marrow
mononuclear cells enriched for megakaryoblasts (CD34-),
T cells (CD3+) and granulocytes (CD66b+), from P005.
All cell populations had > 95 % purity.
Expression of wild type ANLN was absent in granulo-
cytes from healthy subjects, PMF patients and P005.
On the other hand, ANLN expression was present in
CD34+ cells from a subset of AML patients and in
both CD34+ and CD34- mononuclear populations from
P005 (Fig. 2a). These data suggest that wild type ANLN is
Fig. 1 t(7;12)(p15;p13) and ETV6-ANLN fusion transcript. a Cytogenetic analysis revealing the t(7;12)(p15;p13) b Sanger sequencing of the fusion transcript,
demonstrating the fusion of ETV6 exon 1 to ANLN exon 2. c Putative fusion protein highlighting ETV6 exon 1 and ANLN Anilin and PH domains
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not expressed in mature granulocytes, but only in CD34+
cells from a subset of AML patients. We did not study the
expression of ANLN in CD34+ cells from healthy donors,
therefore we cannot rule out ANLN expression in normal
CD34+ cells.
On the other hand, the fusion transcript was present in
all P005 cell subpopulations (Granulocytes, T lympho-
cytes, CD34+ blasts and CD34- mononuclear cells), sug-
gesting that the translocation may have occurred in a
pluripotent hematopoietic stem cell or an early precursor
(Fig. 2b). As expected, no fusion transcript was detected
in other individuals.
While more common in lymphoid malignancies, such
as acute lymphoblastic leukemia, ETV6 translocations
are uncommon in myeloid neoplasms. In a study of
9,550 patients with myeloid neoplasms, ETV6 transloca-
tions were found in 0.5 % of patients, occurring in only
0.3 % of myeloproliferative neoplasms [1].
Since the fusion gene we identified retains only the
first exon of ETV6, while maintaining the integrity of
the ANLN gene, we speculate that the oncogenic mech-
anism can be related to deregulated ANLN expression.
Indeed, previous studies have reported that ANLN is
overexpressed in a variety of human cancers such as
lung [6], breast [7] and endometrial cancer [8]. In
addition, increased ANLN expression has been linked to
tumor progression [8], and inhibition of ANLN in lung
cancer cells decreases cell viability and increases cell size
and ploidy, probably secondary to defective cytokinesis
[6]. Thus, ANLN seems to play an important role in cell
division, and increased expression of ANLN has been
shown to induce DNA synthesis in lung cancer cells [6].
Similar results have been shown in breast cancer,
where inhibition of ANLN expression abrogates cell
proliferation and colony forming ability of breast
cancer cell lines. We are not aware of published data
about ANLN expression in hematological malignan-
cies, and the precise role of the ETV6-ANLN fusion
transcript in the pathogenesis of myeloid malignan-
cies with the t(7;12)(p15;p13) translocation still needs
to be defined, but we believe that deregulated ANLN
expression leading to increased cellular proliferation
might play a role.
Conclusions
We have demonstrated that the recurrent AML associated
translocation t(7;12)(p15;p13) leads to the formation of
the novel fusion gene ETV6-ANLN that is expressed in
the myeloid and lymphoid lineages. To the best of our
knowledge, this is the first report implicating the
actin-binding protein ANLN in the pathogenesis of AML
and other myeloid neoplasms.
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